Childhood cancer remains one of the most significant health challenges facing children and families worldwide. While advances in diagnosis and treatment have dramatically improved survival rates for many childhood cancers, access to appropriate medicines remains uneven. In many low- and middle-income countries, children may struggle to receive essential cancer medicines because of high costs, limited availability, supply-chain disruptions, and a lack of commercially attractive markets for paediatric formulations.

A new strategy focused on building a healthier market for childhood cancer medicines could help address these challenges by bringing together governments, healthcare institutions, pharmaceutical companies, international organisations, researchers, and patient advocates.

Creating a Sustainable Market

One of the central challenges is that the market for childhood cancer medicines is relatively small compared with the adult cancer market. Pharmaceutical manufacturers may therefore have limited commercial incentives to develop, register, manufacture, and distribute medicines specifically designed for children.

A healthier market strategy needs to make paediatric oncology medicines commercially sustainable while keeping them affordable. Governments and international organisations can contribute through mechanisms such as pooled procurement, long-term purchasing commitments, market-shaping initiatives, and financial incentives for manufacturers.

Predictable demand can encourage manufacturers to invest in production capacity and improve the reliability of medicine supplies. Instead of responding only when shortages occur, health systems can use coordinated purchasing and forecasting to provide manufacturers with clearer information about future requirements.

Improving Access to Paediatric Formulations

Children are not simply smaller versions of adults. Their medicines often require appropriate doses, formulations, strengths, and administration methods. However, in some settings, healthcare professionals may have limited access to child-friendly formulations.

Developing dispersible tablets, oral liquids, appropriate-dose tablets, and other paediatric formulations can make treatment safer and easier to administer. Standardised formulations can also reduce the need for healthcare workers or caregivers to manipulate adult medicines to obtain paediatric doses.

Regulatory agencies can support this process by establishing clear pathways for the development and approval of paediatric medicines while maintaining appropriate standards for quality, safety, and effectiveness.

Strengthening Supply Chains

Even when medicines are affordable, they cannot benefit patients if they are unavailable when treatment is needed. Childhood cancer treatment often follows carefully planned protocols, making interruptions particularly concerning.

A healthier market therefore requires stronger supply-chain systems. Better forecasting, inventory management, procurement planning, and regional distribution networks can help reduce stock-outs. Countries can also strengthen monitoring systems to identify shortages before they become critical.

Manufacturers, procurement agencies, hospitals, and governments should share information about demand and supply. Improved transparency can help identify vulnerable points in the supply chain and allow corrective action earlier.

Encouraging Innovation and Competition

Innovation should remain an important component of the strategy. Research institutions and pharmaceutical companies can work together to develop new medicines and improve existing treatments.

At the same time, competition can help support affordability and availability. Where appropriate, policies that encourage multiple qualified manufacturers to enter the market can reduce dependence on a single supplier. Technology transfer and local or regional manufacturing partnerships may also strengthen supply security in countries that currently rely heavily on imports.

However, competition must be accompanied by rigorous quality standards. Medicines supplied to children must meet established requirements for safety, efficacy, and manufacturing quality.

Using Data to Shape the Market

Reliable data is essential for making the market function effectively. Countries need accurate information about the number of children requiring cancer treatment, the medicines used in treatment protocols, expected demand, procurement volumes, prices, and supply disruptions.

Better data can help governments and procurement organisations estimate future requirements more accurately. It can also provide manufacturers with greater visibility into potential demand.

International collaboration can further support the development of common data standards and forecasting tools, making it easier to coordinate procurement across countries and regions.

Putting Children at the Centre

Any strategy for improving the market for childhood cancer medicines must ultimately focus on children and their families. Affordability, availability, quality, and appropriate formulations are not simply commercial considerations—they directly affect whether children can receive timely treatment.

Healthcare professionals and patient representatives should therefore have a meaningful role in designing policies and procurement systems. Their experience can help identify practical barriers that may not be visible in market data alone.

Looking Ahead

Building a healthier market for childhood cancer medicines requires more than increasing medicine production. It requires coordinated action across the entire ecosystem—from research and regulation to manufacturing, procurement, distribution, and clinical care.

A combination of predictable demand, responsible market incentives, stronger supply chains, paediatric-focused product development, reliable data, and international cooperation could create a more sustainable environment for childhood cancer medicines.

The objective is clear: medicines that children need should be available, affordable, quality-assured, and appropriate for their treatment. By reshaping the market around these priorities, health systems can help ensure that advances in childhood cancer care translate into better and more equitable access for children everywhere.